RBC Capital Maintains Outperform on Eli Lilly, Raises Price Target to $1500
Eli Lilly and Company
Eli Lilly and Company LLY | 0.00 |
RBC Capital analyst Trung Huynh maintains Eli Lilly (NYSE:
LLY) with a Outperform and raises the price target from $1250 to $1500.
